Organ Procurement Unit, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Cardiovascular Research Foundation of Southern California, Beverly Hills, CA, USA; Southern California Medical Education Consortium, Temecula Valley Hospital, Universal Health System, Temecula, CA, USA.
Transpl Immunol. 2022 Oct;74:101658. doi: 10.1016/j.trim.2022.101658. Epub 2022 Jun 28.
Nearly one year from the onset of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, safe and effective vaccines began distribution around the world. This study aimed to assess the rate of COVID-19 disease among vaccinated kidney transplant patients and the types of symptoms found within them.
This cross-sectional study was performed at the transplant ward and Organ Procurement Unit of Sina Hospital, Tehran, Iran. As a sample size, 159 cadavers' kidney recipients received two doses of the Sinopharm SARS-CoV-2 vaccine. The required data were collected using a checklist via conducting a face-to-face interview.
The mean age of the vaccinated participants was 49.44 ± 13.87 years old. There were 73 (45.91%) vaccinated cases of SARS-CoV-2 infection during the study period, 18 cases (12.6%) occurred among fully vaccinated individuals, and 53 cases (33.3%) were among individuals who had received only one dose of vaccine. 45% of the fully vaccinated patients (received 2 doses vaccine) contracted SARS-CoV-2 from their families; 35% were infected through participation in social events (35%). There was a significant difference in disease severity levels between the fully vaccinated group and the one-dose vaccinated (p < 0.023). The severe disease occurred in 2 patients after vaccination, who were subsequently admitted to the hospital. There was a significant difference between the number of kidney transplant days and infection with SARS-CoV-2 before (P = 0.15) and after vaccination (p < 0.015).
Even after vaccination, kidney recipients are still at the risk of contracting SARS-CoV-2. In addition to these results, the efficacy of vaccination in preventing death caused by SARS-CoV-2 was confirmed.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)大流行开始近一年后,安全有效的疫苗开始在全球范围内分发。本研究旨在评估接种 COVID-19 疫苗的肾移植患者的疾病发生率以及其中发现的症状类型。
本横断面研究在伊朗德黑兰 Sina 医院的移植病房和器官采购单位进行。作为样本量,159 名尸体供肾受者接受了两剂国药控股 SARS-CoV-2 疫苗。通过面对面访谈使用检查表收集所需数据。
接种疫苗参与者的平均年龄为 49.44±13.87 岁。在研究期间,有 73 例(45.91%)接种 SARS-CoV-2 感染病例,18 例(12.6%)发生在完全接种疫苗的个体中,53 例(33.3%)发生在仅接种一剂疫苗的个体中。45%的完全接种疫苗患者(接种 2 剂疫苗)从家庭中感染了 SARS-CoV-2;35%是通过参加社交活动(35%)感染的。完全接种组和一剂接种组之间疾病严重程度水平有显著差异(p<0.023)。接种后有 2 例患者出现严重疾病,随后住院治疗。肾移植天数与接种疫苗前(P=0.15)和接种疫苗后(p<0.015)感染 SARS-CoV-2 之间存在显著差异。
即使接种疫苗后,肾移植受者仍有感染 SARS-CoV-2 的风险。除了这些结果外,还证实了疫苗预防 SARS-CoV-2 死亡的功效。